|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.45 TWD | -0.23% |
|
-6.16% | +21.71% |
Mycenax Biotech Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 732.28 million compared to TWD 774.27 million a year ago. Net loss was TWD 453.63 million compared to TWD 89.86 million a year ago.
Basic loss per share from continuing operations was TWD 2.74 compared to TWD 0.61 a year ago. Diluted loss per share from continuing operations was TWD 2.74 compared to TWD 0.61 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +21.71% | 275M | |
| -3.46% | 102B | |
| +1.41% | 96.29B | |
| +2.13% | 22.18B | |
| -15.84% | 21.2B | |
| -9.21% | 18.31B | |
| -39.98% | 17.38B | |
| -14.65% | 16.36B | |
| +4.39% | 13.97B | |
| +31.35% | 12.17B |
MYCENAX BIOTECH INC. 
